Mumbai-based Lupin Ltd acquired brands Ondero and Ondero-Met from drug maker Boehringer Ingelheim International GmbH, Germany. This also includes the acquisition of trademark rights associated with these brands.
According to Lupin, an estimated 77 million people above the age of 18 years in India have Type-2 Diabetes, while nearly 25 million are pre-diabetic, at higher risk of developing diabetes in the future. “Ondero (Linagliptin) and Ondero – Met (Linagliptin + Metformin) are the gold standard in diabetes management,” it said.
“With the acquisition of Ondero and Ondero – Met, we continue to offer a wide portfolio of products to enable access to medication for patients, and further consolidate our position as a market leader in the anti-diabetes segment,” noted Nilesh Gupta, managing director, Lupin.
Earlier this month, Lupin said that it had received approval from the U.S. Food and Drug Administration for its abbreviated new drug application for a generic version of Bromday Ophthalmic Solution 0.09 percent, which is produced by Bausch & Lomb Inc.
Last updated: December 26th, 2025
